CompletedNot Applicable

Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma

France137 participantsStarted 2016-06-01

Plain-language summary

The purpose of this study is to determine if the XPO1 E571K mutation could be used as molecular residual disease biomarker in classical Hodgkin's lymphoma. To determine the interest of the mutation assessment by digital Polymerase Chain Reaction, sensitivity and specificity after 2 courses of chemotherapy (C2) will be compared with the deltaSUVmax determined by Positron Emission Tomography after C2 and at end of treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years * Pathologically confirmed, recent diagnosis of classical Hodgkin Lymphoma * treatment planned with Adriamycin Bleamycin Vinblastine Dacarbazine (ABVD) or Bleomycin Etoposide Adriamycin Cyclophosphamide Vincristine Procarbazine Prednisone (BEACOPP) regimen (and radiotherapy if applicable) * all stages (Ann Arbor I - IV) * Written informed consent * Patient affiliated or beneficiary of a benefit system * untreated patient (no corticosteroids or chemotherapy) Exclusion Criteria: * No informed consent * Treatment by ABVD or BEACOPP not indicated * Previously treated Hodgkin lymphoma (including corticosteroids) * Patients who are pregnant or lactating * Active Hepatitis B or Hepatitis C infection * Known human immunodeficiency virus (HIV) infection - Patient with no social protection * Patient under tutorship or curatorship * Patient not affiliated of beneficiary of a benefit system * Medical contraindication to PET/CT

What they're measuring

If the mutation can be used as a molecular minimal residual disease biomarker

Timeframe: 56 days

Trial details

NCT IDNCT02815137

SponsorCentre Henri Becquerel

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-12-07